Eliquis fails to beat Lovenox at clot-fighting after surgery

In a study that could give versions of Sanofi's Lovenox a boost, the new Bristol-Myers Squibb ($BMY) and Pfizer ($PFE) anti-coagulant Eliquis failed to prove superior to the older drug in preventing clots after surgery. The ADOPT trial showed Lovenox staved off venous thromboembolism and VTE-related death in all but 3.1% of patients, while Eliquis prevented VTE and VTE death in all but 2.7%. Lovenox's lone generic competitor comes from Momenta Pharmaceuticals ($MNTA) and Sandoz, while another is waiting in the wings. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.